RFK Jr.’s Claims About Remdesivir and COVID-19 Hospital Incentives: A Fact Check

Recent claims circulating online, popularized by Robert F. Kennedy Jr., allege that hospitals intentionally harmed COVID-19 patients by administering remdesivir, motivated by financial incentives from the government. These claims suggest remdesivir is a toxic drug that causes organ failure and that hospitals were incentivized to use it regardless of its efficacy. This article examines these allegations, separating fact from misinformation.

The Claims: Remdesivir, Hospital Payments, and Intentional Harm

The core of the claim centers around several points:

• Remdesivir is inherently toxic: Allegations state the drug causes kidney failure, heart failure, and multi-organ collapse.
• Financial incentives drove remdesivir use: Hospitals received $13,000 for each “COVID” patient and $39,000 for putting a patient on a ventilator, with an additional 20% bonus for administering remdesivir.
• Hospitals were “murdering” patients: The implication is that hospitals knowingly used a harmful drug for financial gain.

What is Remdesivir?

Remdesivir is an antiviral medication developed by Gilead Sciences. Research began in 2009, initially targeting hepatitis C and respiratory syncytial virus, before being investigated for its potential against other viruses, including Ebola and, later, COVID-19. In April 2020, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), announced that data from a multinational clinical trial showed remdesivir had a “clear-cut significant positive effect in diminishing time to recovery” for patients with COVID-19 [1]. The drug works by interfering with the virus’s ability to replicate.

Fact-Checking the Allegations

Remdesivir’s Toxicity

While remdesivir, like all medications, has potential side effects, the claim that it routinely causes kidney failure, heart failure, and multi-organ collapse is not supported by scientific evidence. Side effects reported in clinical trials and post-marketing surveillance include liver enzyme elevations and infusion-related reactions. Serious adverse events were observed, but widespread organ failure was not a consistent finding.

Hospital Financial Incentives

It is true that the federal government provided financial assistance to hospitals during the COVID-19 pandemic. However, the characterization of these payments as incentives to use remdesivir is misleading. The Coronavirus Aid, Relief, and Economic Security (CARES) Act provided funding to hospitals to cover increased expenses and lost revenue due to the pandemic.

The claim of a 20% bonus for administering remdesivir is a distortion of the reimbursement structure. Hospitals received a 20% increase in Medicare payments for COVID-19 patients, but this was not specifically tied to the use of remdesivir. The increase applied to the entire hospital bill for COVID-19 patients, regardless of treatment.

Who Developed Remdesivir?

Remdesivir was developed by Gilead Sciences, a pharmaceutical company [2]. Dr. Anthony Fauci and Bill Gates were not involved in its invention, and neither stand to directly profit from its sales. Fauci’s role was as the director of the NIAID, which conducted clinical trials to evaluate the drug’s effectiveness [2]. Remdesivir was also developed through a partnership between Gilead Sciences and the Baric Lab at the University of North Carolina at Chapel Hill [3].

The NIH Trial and Remdesivir’s Effectiveness

The National Institutes of Health (NIH) initiated a clinical trial in February 2020 to assess remdesivir’s efficacy in treating COVID-19 [4]. The trial, led by Dr. Anthony Fauci, showed that patients who received remdesivir recovered faster than those who received a placebo. This led to remdesivir being considered a standard of care for some COVID-19 patients.

Conclusion

The claims that hospitals intentionally harmed COVID-19 patients by administering remdesivir for financial gain are largely unsubstantiated. While financial incentives existed to support hospitals during the pandemic, they were not specifically tied to the use of remdesivir. Remdesivir has potential side effects, but the assertion that it routinely causes severe organ failure is not supported by scientific evidence. The drug was developed by Gilead Sciences, with contributions from academic institutions, and clinical trials indicated it could shorten recovery time for COVID-19 patients.